NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
T.R. Jeffry Evans(University of Glasgow), Jordan Berlin(Dana-Farber Cancer Institute), Aimery de Gramont(Institut Hospitalier Franco Britannique), Sarah P. Blagden(Churchill Hospital), Janet S. Graham(Beatson West of Scotland Cancer Centre), Kristen K. Ciombor(The Ohio State University), Josep Tabernero(Deaconess Hospital)
Cited by 7
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k